Mostrar el registro sencillo del documento
Cardiovascular disease in the antiphospholipid syndrome
dc.creator | Amaya-Amaya J | |
dc.creator | Rojas-Villarraga A | |
dc.creator | Anaya JM. | |
dc.date.accessioned | 2019-01-18T21:33:53Z | |
dc.date.available | 2019-01-18T21:33:53Z | |
dc.date.created | 2014 | |
dc.identifier.uri | http://repositorio.mederi.com.co/handle/123456789/260 | |
dc.description.abstract | The prevalence of cardiovascular disease (CVD) in antiphospholipid syndrome (APS) varies from one series to another depending on the definition of CVD and tools used for its detection. Atherosclerosis, the usual cause of CVD, starts when the endothelium becomes damaged and is considered to be an autoimmune-inflammatory disease. The excessive cardiovascular events observed in patients with APS are not fully explained by traditional risk factors. Therefore, several novel risk factors contribute to the development of premature CVD and accelerated vascular damage in those patients. Herein, the significance and outcomes of CVD in APS are reviewed. | en |
dc.format.mimetype | ||
dc.relation.uri | http://www.ncbi.nlm.nih.gov/pubmed/25228729 | |
dc.title | Cardiovascular disease in the antiphospholipid syndrome | |
dc.rights.accessRights | openAccess |
Archivos en el documento
Archivos | Tamaño | Formato | Ver |
---|---|---|---|
No hay archivos asociados a este documento. |
Este documento aparece en la(s) siguiente(s) colección(ones)
-
Investigación clínica [389]